Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Prucalopride→

Prucalopride Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
179474-81-8
Molecular formula
C18H26ClN3O3
Molecular weight
367.9 g/mol
Drug class
Selective serotonin 5-HT4 receptor agonistGastrointestinal prokinetic agent
Mechanism of action
Selectively activates 5-HT4 receptors and stimulates colonic peristalsis, including high-amplitude propagating contractions, thereby increasing bowel motility.
Indications / reported uses
  • Chronic idiopathic constipation in adults

Sources: DailyMed — Prucalopride tablets prescribing information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Prucalopride Environmental Risk Assessment (ERA) (the Prucalopride ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.